SG11202012496XA - Promoting immune responses - Google Patents

Promoting immune responses

Info

Publication number
SG11202012496XA
SG11202012496XA SG11202012496XA SG11202012496XA SG11202012496XA SG 11202012496X A SG11202012496X A SG 11202012496XA SG 11202012496X A SG11202012496X A SG 11202012496XA SG 11202012496X A SG11202012496X A SG 11202012496XA SG 11202012496X A SG11202012496X A SG 11202012496XA
Authority
SG
Singapore
Prior art keywords
immune responses
promoting immune
promoting
responses
immune
Prior art date
Application number
SG11202012496XA
Inventor
Feng Shao
Ping Zhou
Yang She
Huabin He
Peng Li
Jingjin Ding
Wenqing Gao
Original Assignee
National Institute Of Biological Sciences Beijing
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Institute Of Biological Sciences Beijing filed Critical National Institute Of Biological Sciences Beijing
Publication of SG11202012496XA publication Critical patent/SG11202012496XA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549Sugars, nucleosides, nucleotides or nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202012496XA 2018-06-14 2019-06-11 Promoting immune responses SG11202012496XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018091177 2018-06-14
PCT/CN2019/090647 WO2019238024A1 (en) 2018-06-14 2019-06-11 Promoting immune responses

Publications (1)

Publication Number Publication Date
SG11202012496XA true SG11202012496XA (en) 2021-01-28

Family

ID=68842704

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202012496XA SG11202012496XA (en) 2018-06-14 2019-06-11 Promoting immune responses

Country Status (9)

Country Link
US (1) US11229707B2 (en)
EP (1) EP3752163A4 (en)
JP (1) JP2021527133A (en)
KR (1) KR20210020104A (en)
CN (1) CN111971049A (en)
AU (1) AU2019284192A1 (en)
CA (1) CA3103724A1 (en)
SG (1) SG11202012496XA (en)
WO (1) WO2019238024A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022127914A1 (en) 2020-12-18 2022-06-23 Pyrotech (Beijing) Biotechnology Co., Ltd. Nucleoside-thiodiphosphate-heptose compounds for treating conditions associated with alpk1 activity
WO2023051675A1 (en) 2021-09-30 2023-04-06 Pyrotech (Beijing) Biotechnology Co., Ltd. Nucleoside-diphosphate-heptose compounds for treating conditions associated with alpk1 activity
CN117517657B (en) * 2024-01-08 2024-04-09 中国农业科学院北京畜牧兽医研究所 Application of LNX1 gene or protein in regulation of avian innate immune response

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6044499A (en) * 1998-09-25 2000-04-17 Diagnon Corporation High throughput assay method for enzymes which metabolically hydrolyze nucleoside triphosphates and an assay system therefor
JPWO2007119815A1 (en) * 2006-04-14 2009-08-27 協和発酵キリン株式会社 Toll-like receptor 9 agonist
EP3204014B1 (en) * 2014-10-10 2020-07-01 The Governing Council of the University of Toronto Methods of modulating immune system responses
JP2020507616A (en) * 2017-02-17 2020-03-12 アイビタ バイオメディカル インコーポレイテッド Methods of enhancing tumor immunogenicity using modified tumor cells and modified dendritic cells and compositions of autologous cancer immunotherapy products
JP2021500394A (en) * 2017-10-27 2021-01-07 シャンハイ・ヤオ・ユアン・バイオテクノロジー・カンパニー・リミテッド Compositions and Methods for Modulating an Immune Response by Activating α-Protein Kinase 1

Also Published As

Publication number Publication date
US11229707B2 (en) 2022-01-25
AU2019284192A1 (en) 2021-01-28
US20200405869A1 (en) 2020-12-31
KR20210020104A (en) 2021-02-23
EP3752163A4 (en) 2021-04-07
CN111971049A (en) 2020-11-20
CA3103724A1 (en) 2019-12-19
JP2021527133A (en) 2021-10-11
EP3752163A1 (en) 2020-12-23
WO2019238024A1 (en) 2019-12-19

Similar Documents

Publication Publication Date Title
CA186068S (en) Food preparation device
CA185923S (en) Toaster
IL278864A (en) Shared antigens
IL264557A (en) Biomaterials for modulating immune responses
AU201815480S (en) Blender
CA184989S (en) Uroflowmeter
PL3622862T3 (en) Playpen
ZA201903369B (en) Nutcracker
SG11202012496XA (en) Promoting immune responses
DK3571208T3 (en) IMMUNE PROTEASOMINHIBITORS
GB201918689D0 (en) n
GB2567755B (en) Cooker
PL3807576T3 (en) Cooking device
PL3518617T3 (en) Cooking device
GB201805799D0 (en) b
CA186910S (en) Broiler
AU201811706S (en) Egg poachers
GB2567330B (en) Cooker
CA185924S (en) Toaster
ZA202100026B (en) Complex for enhancing immune response
CA185309S (en) Armchair
ZAA201801262S (en) Toaster
GB201901594D0 (en) Cooking device
PL3732397T3 (en) Cooker
GB201814379D0 (en) Concept four